ES2145265T3 - Sustancias de fijacion para anticuerpos y su utilizacion para analisis inmunologicos o vacunas. - Google Patents

Sustancias de fijacion para anticuerpos y su utilizacion para analisis inmunologicos o vacunas.

Info

Publication number
ES2145265T3
ES2145265T3 ES95907632T ES95907632T ES2145265T3 ES 2145265 T3 ES2145265 T3 ES 2145265T3 ES 95907632 T ES95907632 T ES 95907632T ES 95907632 T ES95907632 T ES 95907632T ES 2145265 T3 ES2145265 T3 ES 2145265T3
Authority
ES
Spain
Prior art keywords
groups
amino acid
sup
replaced
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95907632T
Other languages
English (en)
Inventor
Christoph Seidel
Rupert Herrmann
Eva Hoess
Hans-Georg Batz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2145265T3 publication Critical patent/ES2145265T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A SUSTANCIA DE LIGAZON INMUNOLOGICA PARA ANTICUERPOS Y SU UTILIZACION EN INMUNOENSAYOS Y COMO VACUNA. LA SUSTANCIA DE LIGAZON INMUNOLOGICA, QUE ENLAZA ESPECIFICAMENTE CON UN ANTICUERPO ESPECIALMENTE DIRIGIDO A UN EPITOPE CON UNA SECUENCIA DE AMINOACIDOS NATURAL Y QUE PORTA UN MARCADO DETECTABLE O BIEN ESTA ENLAZADO EN ESTADO EN FASE SOLIDA O PUEDE SER ENLAZADO LA FASE SOLIDA POR MEDIO DE LIGAZON DE MOLECULA O ESTA LIGADO A UNA MOLECULA INMUNOLOGICA CONTENIENDO EPITOPE DE CELULAS T O A UN PORTADOR DE MOLECULA DE PROTEINA, CARACTERIZANDOSE DE TAL MODO QUE LA SUSTANCIA DE LIGAZON ESPECIFICA CONSTITUYE UNA SECUENCIA DE AMINOACIDOS CORRESPONDIENTE AL EPITOPE NATURAL. LA SECUENCIA LIGADA A UN PEPTIDO O A UN AMINOACIDO SE CAMBIA DE TAL MODO QUE A) UNO O MULTIPLES GRUPOS DE ENLACE DE PEPTIDO - CO - NH SON REEMPLAZADOS POR MEDIO DE DOS O TRES PUENTES DE ATOMO DIFERENTE DE ELLOS, B) LAS CADENAS LATERALES DE AMINOACIDO SON ACORTADAS POR MEDIO DE GRUPOS - CH2 O ALARGADAS POR MEDIO DE GRUPOS - CH2, S, - O, - NH, - SO2 O - CO, C) UNO O MAS AMINOACIDOS SON REEMPLAZADOS POR AMINOACIDOS L O D NO BIOGENICOS DEL TIPO HR''N - Y - COOH, DONDE Y ES UN GRUPO (CH2)N CON N = 2,8 O UN GRUPO - CH - (CH2)M CR{SUP,1}R{SUP,2}R{SUP,3} CON M = 0,3, DONDE R{SUP1,}, R{SUP,2} Y R{SUP,3}, QUE PUEDEN SER IGUALES O DIFERENTES, SON HIDROGENO, UN RADICAL C1 - C4 ALQUILO RAMIFICADO O NO RAMIFICADO O FENILO, NAFTILO O RADICAL HETEROARILO DE 5 O 6 MIEMBROS, CONTENIENDO O , S - O N -, QUE PUEDE SER SUSTITUIDO POR GRUPOS METILO, HALURO, NH2, OH O CARBOXI, O DONDE Y ES UN GRUPO CHR, DONDE R ES UNA CADENA LATERAL DE UN AMINOACIDO NATURAL EN DONDE LOS GRUPOS - CH2 SON REEMPLAZADOS POR - S, NH, - CH =, - SO2, - CO, O - O, DONDE UNO O MAS ATOMOS H SON SUSTITUIDOS POR GRUPOS METILO, HN2, CARBOXILO, SH, HALURO O HIDROXI, DONDE EN TODOS LOS CASOS Y FORMA UNA AGRUPACION DIFERENTE DE CUALQUIER AMINOACIDO NATURAL O DONDE R'' ES UN GRUPO METILO, ETILO O FENILO E Y ES UN GRUPO CHR, EN DONDE R ES UNA CADENA NATURAL DE UN AMINOACIDO NATURAL.
ES95907632T 1994-01-31 1995-01-31 Sustancias de fijacion para anticuerpos y su utilizacion para analisis inmunologicos o vacunas. Expired - Lifetime ES2145265T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4402756A DE4402756A1 (de) 1994-01-31 1994-01-31 Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine

Publications (1)

Publication Number Publication Date
ES2145265T3 true ES2145265T3 (es) 2000-07-01

Family

ID=6509044

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95907632T Expired - Lifetime ES2145265T3 (es) 1994-01-31 1995-01-31 Sustancias de fijacion para anticuerpos y su utilizacion para analisis inmunologicos o vacunas.

Country Status (7)

Country Link
US (1) US6210901B1 (es)
EP (1) EP0741869B1 (es)
JP (1) JP3387928B2 (es)
AT (1) ATE191568T1 (es)
DE (2) DE4402756A1 (es)
ES (1) ES2145265T3 (es)
WO (1) WO1995020764A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804371A (en) * 1994-07-25 1998-09-08 Boehringer Mannheim Gmbh Hapten-labelled peptides
US5837482A (en) * 1997-01-23 1998-11-17 Minnesota Mining And Manufacturing Company Culture medium and methods for detecting staphylococci
EP1131345A1 (en) * 1998-11-20 2001-09-12 Bio Merieux Synthetic polypeptides corresponding to the hepatitis c virus (hcv) and applications
WO2002008722A2 (en) * 2000-07-12 2002-01-31 Werner Naser Direct assessment of relative concentrations of variants of an epitope on a dimeric molecule
DE60133558D1 (de) * 2000-07-12 2008-05-21 Werner Naser Direkte bestimmung des quotients von analyt- zu referenzmolekülen
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
CA2462651A1 (en) * 2001-10-05 2003-04-17 Novozymes A/S Kit for predicting binding of a specific antibody to a potential immunogen and method of screening
EP1987843A3 (en) * 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
WO2009121024A2 (en) * 2008-03-27 2009-10-01 The Regents Of The University Of California Methods for detecting antibodies
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
USD800912S1 (en) 2016-06-17 2017-10-24 Abreos Biosciences, Inc. Point-of-care diagnostic device
WO2018031887A1 (en) 2016-08-12 2018-02-15 Abreos Biosciences, Inc. Detection and quantification of natalizumab

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204096A (en) * 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
GB9005829D0 (en) * 1990-03-15 1990-05-09 Proteus Biotech Ltd Synthetic polypeptides
ES2152922T3 (es) * 1990-04-06 2001-02-16 Genelabs Tech Inc Epitopos del virus de la hepatitis c.
NZ246059A (en) * 1991-12-03 1995-08-28 Proteus Molecular Design Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits
WO1993023031A1 (en) * 1992-05-08 1993-11-25 The Biomembrane Institute Multivalent mimetics and peptide mimetics for blocking carbohydrate-dependent cellular interaction and for eliciting anticarbohydrate t-cell response
GB9215129D0 (en) * 1992-07-16 1992-08-26 Medical Res Council Development relating to human immunodeficiency viruses
JPH08511007A (ja) * 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド

Also Published As

Publication number Publication date
DE4402756A1 (de) 1995-08-03
JPH09508374A (ja) 1997-08-26
WO1995020764A1 (de) 1995-08-03
US6210901B1 (en) 2001-04-03
ATE191568T1 (de) 2000-04-15
EP0741869B1 (de) 2000-04-05
JP3387928B2 (ja) 2003-03-17
DE59508137D1 (de) 2000-05-11
EP0741869A1 (de) 1996-11-13

Similar Documents

Publication Publication Date Title
Lazarides Immunofluorescence studies on the structure of actin filaments in tissue culture cells.
Trombitás et al. Titin extensibility in situ: entropic elasticity of permanently folded and permanently unfolded molecular segments
BR9914829A (pt) Uso de um grupo de polipeptìdeo, proteìna ligadora multivalente, sequências de nucleotìdeos, vetor de expressão, e, célula hospedeira
CY1108603T1 (el) Συστηματα πρωτεϊνων μεταφορας λιπιδιων και η καλλυντικη δερματολογικη εφαρμογη τους
ES2044874T3 (es) Derivados del acido malonico y metodos para su sintesis.
MX9301006A (es) Guanidinas n,n'-disubstituidas y su uso como antaginistas excitadores de aminoacido.
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
DE69531863D1 (de) Verwendung von n-acetyl-l-cystein zur aufhellung von hyperpigmentierter haut
BRPI0417801A (pt) incorporação seletiva de 5-hidroxitriptofano em proteìnas de células mamìferas
AR222359A1 (es) Procedimiento para la purificacion de proteinas de elevado peso molecular
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
DE59102997D1 (de) Chirurgische Klammer.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ES534195A0 (es) Procedimiento para preparar una solucion estable de proteina
CO4810339A1 (es) Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion
RU2014104577A (ru) Оптимизация растворимости иммуносвязывающих средств
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
ES2196008T3 (es) Vacuna del virus de la hepatitis e y procedimiento.
AR008680A1 (es) Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion
CY1108020T1 (el) Μονοκλωνικα αντισωματα στον ανθρωπινο υποδοχεα ldl, η παραγωγη και χρηση τους
ES2148617T3 (es) Reactivos perfeccionados para un inmunoensayo de cannabinoides.
BR9811861A (pt) Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh)
CY1105683T1 (el) Ενεργο συζυγες ακανθοχοιρικης πρωτεϊνης, μεθοδος για την παρασκευη και χρηση αυτου
CY1105763T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 741869

Country of ref document: ES